Episode 182 - May 8, 2026

What It Covers

Biotech Hangout Episode 182 covers a record-breaking Q1 2026 secondary offering environment, three new M&A deals totaling over $6 billion, FDA leadership instability under Commissioner Makary, clinical data from Cytokinetics, Artiva, and J&J, and the accelerating influence of Chinese biotech assets on U.S. drug development pipelines.

Key Questions Answered

• •Secondary Offering Saturation Risk: Q1 2026 set an all-time record for biotech secondary offerings, with companies like Cytokinetics, Avallo, and Artiva raising hundreds of millions each. The key risk indicator to monitor is generalist investor participation — when generalists are absent, excess paper supply historically kills biotech rallies. Current raises appear data-driven rather than opportunistic, distinguishing this cycle from the 2020 excess.
• •M&A Recycling Mechanism: Three deals closed this week — Angelini acquiring Catalyst Pharmaceuticals for $4.1 billion, Bayer acquiring Perfuse Therapeutics for $300 million upfront, and UCB acquiring Candid Therapeutics for $2 billion upfront. For venture-backed startups, M&A remains the primary liquidity mechanism, recycling LP capital back into early-stage biotech. Q1 2026 M&A volume was described as healthy, sustaining the ecosystem's funding cycle.
• •China Asset Licensing Premium Rising: Candid Therapeutics' $2 billion UCB acquisition was built on T-cell engager assets licensed from China. The strategy of licensing Chinese drug candidates and forming U.S. companies around them is now commanding higher premiums than early movers paid. Investors evaluating this approach must account for China's rapid innovation pace, which risks making recently licensed assets obsolete within months of deal close.
• •Commercial vs. Development Stage Rotation: Investor appetite in 2026 has shifted toward development-stage biotechs chasing binary readout upside, leaving commercial-stage names like BioMarin undervalued despite conservative valuation support. Companies with strong launches — including Agios in thalassemia — are seeing muted stock responses even on beats. Investors should monitor whether large-cap M&A of undervalued commercial biotechs triggers a rotation back into this segment.
• •FDA Instability Creating Approval Unpredictability: Commissioner Makary faces roughly 50/50 odds of remaining through May 2026 per political prediction markets. The agency laid off 3,500 staff and is now attempting to rehire 3,200. Contradictory guidance across divisions, suppressed internal vaccine safety reports, and White House pressure on approval decisions — including fruit-flavored vape authorization — are creating inconsistent regulatory pathways that vary significantly by therapeutic area and division.
• •Neurofilament as ALS Approval Biomarker: The FDA's CDER division signaled willingness to accept neurofilament light chain reductions as a basis for accelerated approval in ALS, following the Tofersen SOD1 precedent where the drug failed placebo-controlled endpoints but lowered neurofilament by roughly 40%. Investors tracking neurodegenerative programs should assess whether neurofilament reduction magnitude and consistency clears the signal-to-noise threshold, as the FDA has not defined a minimum clinically meaningful reduction threshold.